Reviewing the bioequivalence study of the antidiabetic drug Semaglutide of MSN Laboratories, the Subject Expert Committee ...

Sun Pharma's clinical trial failure impacts SPARC stock, highlighting the challenges in derma-oncology research.

Drug major Cipla has received approval from the Subject Expert Committee (SEC) functional under the Central Drug Standard ...

An annual review of clinical trials for Alzheimer's disease highlights a growing number of active trials—and drugs—in the ...

Shares of Sun Pharma Advanced Research Company Ltd (SPARC) plunged nearly 20% on Wednesday on the NSE, after the company ...

Sun Pharma Advanced Research Company (SPARC) psoriasis drug, Vibozilimod (SCD-044), failed to meet primary endpoints in Phase ...

Sun Pharma’s phase 2 trials of SCD-044 to treat moderate to severe psoriasis and atopic dermatitis fails to meet primary endpoint: Our Bureau, Mumbai Wednesday, June 4, 2025, 11 ...

Shares of Sun Pharma Advanced Research Company (SPARC) shares crashed significantly on Wednesday after the company announced ...

Sun Pharma's shares experienced a 0.47 per cent decline, trading at Rs 1,659.80, alongside the sharper fall in SPARC shares ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

SPARC tumbled 19 percent after Phase 2 trials of its psoriasis drug SCD-044 failed to meet primary endpoints. The company ...